[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 4473
81. Awan FT, Lapalombella R, Trotta R, Butchar JP, Yu B, Benson DM Jr, Roda JM, Cheney C, Mo X, Lehman A, Jones J, Flynn J, Jarjoura D, Desjarlais JR, Tridandapani S, Caligiuri MA, Muthusamy N, Byrd JC: CD19 targeting of chronic lymphocytic leukemia with a novel Fc-domain-engineered monoclonal antibody. Blood; 2010 Feb 11;115(6):1204-13
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD19 targeting of chronic lymphocytic leukemia with a novel Fc-domain-engineered monoclonal antibody.
  • CD19 is a B cell-specific antigen expressed on chronic lymphocytic leukemia (CLL) cells but to date has not been effectively targeted with therapeutic monoclonal antibodies.
  • The NK cell-mediated cytolytic and secretory function with XmAb5574 compared with the nonengineered antibody is associated with enhanced NK-cell activation, interferon production, extracellular signal-regulated kinase phosphorylation downstream of Fcgamma receptor, and no increased NK-cell apoptosis.
  • Notably, enhanced NK cell-mediated ADCC with XmAb5574 was enhanced further by lenalidomide.
  • These findings provide strong support for further clinical development of XmAb5574 as both a monotherapy and in combination with lenalidomide for the therapy of CLL and related CD19(+) B-cell malignancies.

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2007 Oct 1;110(7):2569-77 [17440052.001]
  • [Cites] Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4448-55 [17671129.001]
  • [Cites] J Clin Oncol. 2007 Dec 10;25(35):5616-23 [17984186.001]
  • [Cites] Br J Haematol. 2008 Jan;140(1):46-58 [17991300.001]
  • [Cites] Blood. 2008 Apr 15;111(8):4173-83 [18174382.001]
  • [Cites] Nat Immunol. 2008 May;9(5):503-10 [18425107.001]
  • [Cites] Clin Cancer Res. 2008 Jul 15;14(14):4650-7 [18628480.001]
  • [Cites] Cancer Res. 2008 Oct 1;68(19):8049-57 [18829563.001]
  • [Cites] Blood. 2008 Dec 15;112(13):5180-9 [18772452.001]
  • [Cites] Blood. 2009 Apr 16;113(16):3735-43 [19109559.001]
  • [Cites] Blood. 2009 Apr 30;113(18):4352-61 [19147785.001]
  • [Cites] Blood. 2011 Apr 28;117(17):4530-41 [21228331.001]
  • [Cites] Immunol Res. 2000;22(2-3):281-98 [11339363.001]
  • [Cites] Leuk Lymphoma. 2001 Aug;42(4):649-54 [11697493.001]
  • [Cites] Blood. 2002 Feb 15;99(4):1314-9 [11830481.001]
  • [Cites] J Clin Invest. 2002 Oct;110(7):983-92 [12370276.001]
  • [Cites] J Cell Biochem. 2003 May 15;89(2):279-88 [12704791.001]
  • [Cites] Blood. 2004 Mar 1;103(5):1846-54 [14630799.001]
  • [Cites] Ann Hematol. 2004 Oct;83(10):634-45 [15309525.001]
  • [Cites] J Exp Med. 1988 Feb 1;167(2):408-20 [2964496.001]
  • [Cites] Clin Immunol Immunopathol. 1988 May;47(2):219-29 [3258212.001]
  • [Cites] J Exp Med. 1990 Apr 1;171(4):1333-45 [2139103.001]
  • [Cites] Cancer Immunol Immunother. 1991;32(6):364-72 [1706642.001]
  • [Cites] Blood. 1994 Mar 1;83(5):1390-7 [8118040.001]
  • [Cites] Cancer Res. 1995 Feb 15;55(4):840-6 [7531616.001]
  • [Cites] Immunity. 1995 Jul;3(1):39-50 [7542548.001]
  • [Cites] Nature. 1995 Jul 27;376(6538):352-5 [7543183.001]
  • [Cites] Clin Lymphoma Myeloma. 2007 Aug;7 Suppl 5:S192-8 [17877844.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Dec 5;92(25):11558-62 [8524803.001]
  • [Cites] Blood. 1995 Dec 15;86(12):4389-99 [8541526.001]
  • [Cites] Blood. 1996 Jun 15;87(12):4990-7 [8652811.001]
  • [Cites] J Immunol. 1996 Jul 1;157(1):48-56 [8683154.001]
  • [Cites] J Exp Med. 1996 Sep 1;184(3):1027-35 [9064320.001]
  • [Cites] J Immunol. 1997 Apr 1;158(7):3062-9 [9120258.001]
  • [Cites] J Immunol. 1997 Apr 1;158(7):3148-54 [9120268.001]
  • [Cites] J Immunol. 1997 May 15;158(10):4662-9 [9144478.001]
  • [Cites] J Immunol. 1997 Oct 1;159(7):3278-87 [9317126.001]
  • [Cites] Blood. 1998 Nov 15;92(10):3804-16 [9808574.001]
  • [Cites] J Immunol. 1998 Dec 15;161(12):6648-56 [9862693.001]
  • [Cites] Leuk Lymphoma. 2005 Jan;46(1):87-100 [15621786.001]
  • [Cites] Leukemia. 2005 May;19(5):835-40 [15744340.001]
  • [Cites] Leukemia. 2006 Feb;20(2):272-9 [16341049.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Mar 14;103(11):4005-10 [16537476.001]
  • [Cites] J Clin Invest. 2006 Sep;116(9):2484-92 [16917543.001]
  • [Cites] Crit Rev Oncol Hematol. 2007 Apr;62(1):26-33 [17240158.001]
  • [Cites] Nat Med. 2007 May;13(5):587-96 [17435771.001]
  • [Cites] Adv Immunol. 2007;96:41-101 [17981204.001]
  • (PMID = 19965644.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P01 CA95426; United States / NCI NIH HHS / CA / P50 CA140158; United States / NCI NIH HHS / CA / P01 CA081534; United States / NCI NIH HHS / CA / P01 CA81534; United States / NCRR NIH HHS / RR / UL1 RR025755; United States / NCI NIH HHS / CA / P01 CA095426
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, CD19; 0 / Immunoglobulin Fc Fragments; 0 / RNA, Messenger; EC 2.7.11.24 / Extracellular Signal-Regulated MAP Kinases; EC 3.4.21.- / Granzymes
  • [Other-IDs] NLM/ PMC2826232
  •  go-up   go-down


82. Tedeschi A, Vismara E, Ricci F, Morra E, Montillo M: The spectrum of use of rituximab in chronic lymphocytic leukemia. Onco Targets Ther; 2010;3:227-46
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The spectrum of use of rituximab in chronic lymphocytic leukemia.
  • The monoclonal chimeric anti-CD20 antibody, rituximab, has considerably improved therapeutic outcome in B-cell chronic lymphocytic leukemia.
  • Furthermore the addition of rituximab enabled the eradication of minimal residual disease, which is correlated with the prognosis in a high proportion of patients.
  • Although the role of rituximab as maintenance therapy in low grade non-Hodgkin's lymphomas has been determined, the benefit and optimal schedule in chronic lymphocytic leukemia are still under investigation.
  • This review brings together knowledge of the pharmacokinetics, mechanism of action and clinical use of rituximab in chronic lymphocytic leukemia.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 2000 Dec 14;343(24):1750-7 [11114313.001]
  • [Cites] Clin Cancer Res. 2001 Mar;7(3):709-23 [11297268.001]
  • [Cites] J Clin Oncol. 2001 Apr 15;19(8):2153-64 [11304767.001]
  • [Cites] J Clin Oncol. 2001 Apr 15;19(8):2165-70 [11304768.001]
  • [Cites] Blood. 1975 Aug;46(2):219-34 [1139039.001]
  • [Cites] Br J Haematol. 2001 Aug;114(2):342-8 [11529853.001]
  • [Cites] Haematologica. 2002 Jan;87(1):33-43 [11801463.001]
  • [Cites] Blood. 2002 Feb 1;99(3):754-8 [11806974.001]
  • [Cites] Leuk Lymphoma. 2002 Jan;43(1):149-51 [11908720.001]
  • [Cites] Hematol J. 2001;2(5):300-6 [11920265.001]
  • [Cites] Hematol J. 2002;3(1):7-9 [11960388.001]
  • [Cites] Blood. 2002 May 15;99(10):3554-61 [11986207.001]
  • [Cites] J Clin Immunol. 2002 May;22(3):124-30 [12078853.001]
  • [Cites] Leuk Lymphoma. 2002 Apr;43(4):767-72 [12153163.001]
  • [Cites] Haematologica. 2002 Sep;87(9):918-25 [12217803.001]
  • [Cites] Blood. 2003 Jan 1;101(1):6-14 [12393429.001]
  • [Cites] Br J Haematol. 2002 Dec;119(4):976-84 [12472576.001]
  • [Cites] Semin Oncol. 2003 Feb;30(1 Suppl 2):34-9 [12652463.001]
  • [Cites] Int J Clin Oncol. 2003 Aug;8(4):212-23 [12955576.001]
  • [Cites] Ann Hematol. 2003 Dec;82(12):759-65 [14551737.001]
  • [Cites] Blood. 2004 Jun 15;103(12):4416-23 [14976046.001]
  • [Cites] Clin Lymphoma. 2004 Mar;4(4):220-7 [15072613.001]
  • [Cites] Leuk Lymphoma. 2004 Nov;45(11):2269-73 [15512816.001]
  • [Cites] Curr Dir Autoimmun. 2005;8:140-74 [15564720.001]
  • [Cites] Blood. 2002 Oct 15;100(8):2965-72 [12351409.001]
  • [Cites] Blood. 2002 Nov 1;100(9):3115-20 [12384407.001]
  • [Cites] Blood. 2003 Feb 1;101(3):949-54 [12393572.001]
  • [Cites] Eur J Haematol. 2002 Sep;69(3):129-34 [12406005.001]
  • [Cites] Blood. 2003 Apr 1;101(7):2507-13 [12446458.001]
  • [Cites] Blood. 2003 May 1;101(9):3413-5 [12522009.001]
  • [Cites] J Clin Oncol. 2003 Apr 1;21(7):1278-84 [12663715.001]
  • [Cites] J Clin Oncol. 2003 May 1;21(9):1746-51 [12721250.001]
  • [Cites] N Engl J Med. 2003 May 1;348(18):1764-75 [12724482.001]
  • [Cites] Blood. 2004 Feb 15;103(4):1472-4 [14563637.001]
  • [Cites] Oncogene. 2003 Oct 20;22(47):7359-68 [14576843.001]
  • [Cites] Blood. 2005 Jan 1;105(1):49-53 [15138165.001]
  • [Cites] Leuk Lymphoma. 2004 May;45(5):945-50 [15291353.001]
  • [Cites] J Clin Oncol. 2005 May 1;23(13):2971-9 [15738539.001]
  • [Cites] Haematologica. 2005 Mar;90(3):391-9 [15749671.001]
  • [Cites] J Clin Oncol. 2005 Jun 20;23(18):4070-8 [15767647.001]
  • [Cites] J Clin Oncol. 2005 Jun 20;23(18):4079-88 [15767648.001]
  • [Cites] Cancer. 2006 Jan 15;106(2):337-45 [16353201.001]
  • [Cites] J Clin Oncol. 2006 Apr 1;24(10):1575-81 [16520464.001]
  • [Cites] Cancer Treat Rev. 2006 Aug;32(5):377-89 [16793209.001]
  • [Cites] Blood. 2006 Nov 15;108(10):3295-301 [16873669.001]
  • [Cites] Blood. 2007 Jan 15;109(2):405-11 [17008537.001]
  • [Cites] J Clin Oncol. 2006 Dec 1;24(34):5343-9 [17088571.001]
  • [Cites] Leukemia. 2007 Jan;21(1):12-7 [17109028.001]
  • [Cites] Leuk Lymphoma. 2007 May;48(5):905-11 [17487734.001]
  • [Cites] Cancer. 2007 Jun 1;109(11):2291-8 [17514743.001]
  • [Cites] Leuk Lymphoma. 2007 Jul;48(7):1299-306 [17613757.001]
  • [Cites] Eur J Haematol. 2007 Aug;79(2):107-13 [17635235.001]
  • [Cites] Lancet. 2007 Jul 21;370(9583):230-9 [17658394.001]
  • [Cites] Mol Immunol. 2007 Sep;44(16):3823-37 [17768100.001]
  • [Cites] Cancer. 2008 Jan 1;112(1):119-28 [17999417.001]
  • [Cites] Leuk Lymphoma. 2007 Dec;48(12):2412-7 [18067017.001]
  • [Cites] Clin Cancer Res. 2008 Jan 1;14(1):155-61 [18172266.001]
  • [Cites] J Clin Oncol. 2008 Jan 10;26(2):196-203 [18182662.001]
  • [Cites] Blood. 2008 Jun 15;111(12):5446-56 [18216293.001]
  • [Cites] Blood. 2008 May 15;111(10):4916-21 [18309034.001]
  • [Cites] Haematologica. 2008 Mar;93(3):475-6 [18310545.001]
  • [Cites] Blood. 2008 Jun 1;111(11):5291-7 [18334676.001]
  • [Cites] Lancet. 2008 Mar 22;371(9617):1017-29 [18358929.001]
  • [Cites] Blood. 2008 Aug 15;112(4):975-80 [18411418.001]
  • [Cites] Clin Cancer Res. 2008 Jul 15;14(14):4650-7 [18628480.001]
  • [Cites] Leukemia. 2008 Nov;22(11):2048-53 [18754025.001]
  • [Cites] Cancer. 2008 Oct 15;113(8):2110-8 [18759253.001]
  • [Cites] Leuk Lymphoma. 2008 Oct;49(10):1995-8 [18949622.001]
  • [Cites] J Clin Oncol. 2009 Feb 1;27(4):498-503 [19075274.001]
  • [Cites] Cancer. 2010 May 15;116(10):2360-5 [20225334.001]
  • [Cites] Leuk Lymphoma. 2010 Aug;51(8):1485-93 [20578816.001]
  • [Cites] Expert Rev Hematol. 2010 Apr;3(2):131-48 [21083456.001]
  • [Cites] Blood. 1996 Jun 15;87(12):4990-7 [8652811.001]
  • [Cites] Lancet. 1996 May 25;347(9013):1432-8 [8676625.001]
  • [Cites] Blood. 1998 Aug 15;92(4):1165-71 [9694704.001]
  • [Cites] J Clin Oncol. 1998 Aug;16(8):2825-33 [9704735.001]
  • [Cites] J Clin Pathol. 1998 May;51(5):364-9 [9708202.001]
  • [Cites] Blood. 1999 Oct 1;94(7):2217-24 [10498591.001]
  • [Cites] Leuk Lymphoma. 1999 Dec;36(1-2):57-65 [10613450.001]
  • [Cites] J Clin Oncol. 2000 Jan;18(2):317-24 [10637245.001]
  • [Cites] Leuk Res. 2000 May;24(5):411-5 [10785263.001]
  • [Cites] Blood. 2000 Jun 15;95(12):3900-8 [10845926.001]
  • [Cites] Scand J Immunol. 2000 Jun;51(6):634-41 [10849376.001]
  • [Cites] Cancer Biother Radiopharm. 1997 Jun;12(3):177-86 [10851464.001]
  • [Cites] Blood. 2000 Jul 1;96(1):71-5 [10891432.001]
  • [Cites] Acta Haematol. 1989;81(4):181-5 [2502891.001]
  • [Cites] Cancer. 1981 Jul 1;48(1):198-206 [7237385.001]
  • [Cites] Blood. 1993 Jun 1;81(11):2878-84 [8499626.001]
  • [Cites] J Clin Oncol. 1997 Oct;15(10):3266-74 [9336364.001]
  • [Cites] Eur J Haematol. 1999 Feb;62(2):76-82 [10052709.001]
  • [Cites] J Natl Cancer Inst. 1999 May 19;91(10):861-8 [10340906.001]
  • [Cites] Leuk Lymphoma. 1999 Jun;34(1-2):167-70 [10350345.001]
  • [Cites] Blood. 1999 Sep 15;94(6):1840-7 [10477712.001]
  • [Cites] Blood. 1999 Sep 15;94(6):1848-54 [10477713.001]
  • [Cites] N Engl J Med. 2000 Dec 28;343(26):1910-6 [11136261.001]
  • [Cites] J Clin Oncol. 2001 Mar 1;19(5):1414-20 [11230486.001]
  • [Cites] Blood. 2001 Sep 1;98(5):1326-31 [11520778.001]
  • [Cites] Br J Haematol. 2001 Sep;114(4):800-9 [11564066.001]
  • [Cites] Leukemia. 2001 Oct;15(10):1619-26 [11587221.001]
  • [Cites] Blood. 2001 Oct 15;98(8):2319-25 [11588025.001]
  • [Cites] J Clin Oncol. 2002 Sep 15;20(18):3891-7 [12228210.001]
  • [Cites] J Clin Oncol. 2009 Feb 1;27(4):491-7 [19075280.001]
  • [Cites] Cancer. 2009 Jan 15;115(2):373-80 [19117034.001]
  • [Cites] Leuk Lymphoma. 2009 Mar;50(3):514-6 [19347738.001]
  • [Cites] Blood. 2009 Sep 3;114(10):2044-50 [19553638.001]
  • [Cites] Leuk Res. 2010 Mar;34(3):284-8 [19646755.001]
  • [Cites] Leukemia. 2009 Oct;23(10):1779-89 [19693094.001]
  • [Cites] J Clin Oncol. 2009 Sep 20;27(27):4578-84 [19704063.001]
  • [Cites] Blood. 2010 Jan 21;115(3):489-95 [19843887.001]
  • [Cites] Leuk Lymphoma. 2010 Jan;51(1):107-13 [20001234.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2009;:440-9 [20008230.001]
  • [Cites] Cancer. 2010 May 1;116(9):2180-7 [20187101.001]
  • [Cites] J Clin Oncol. 2010 Apr 1;28(10):1756-65 [20194844.001]
  • (PMID = 21289858.001).
  • [ISSN] 1178-6930
  • [Journal-full-title] OncoTargets and therapy
  • [ISO-abbreviation] Onco Targets Ther
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] New Zealand
  • [Other-IDs] NLM/ PMC3024887
  • [Keywords] NOTNLM ; B-cell chronic lymphocytic leukemia / first-line treatment / refractory/relapsed / rituximab
  •  go-up   go-down


83. Yang Y, Tian Y, Yan C, Jin X, Tang J, Shen X: Determinants of urinary 8-hydroxy-2'-deoxyguanosine in Chinese children with acute leukemia. Environ Toxicol; 2009 Oct;24(5):446-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Determinants of urinary 8-hydroxy-2'-deoxyguanosine in Chinese children with acute leukemia.
  • The 8-hydroxy-2'-deoxyguanosine (8-OHdG), an oxidized nucleoside of DNA, not only is a widely used biomarker for the measurement of endogenous oxidative DNA damage, but might also be a risk factor for many diseases including cancer.
  • In the present study, the level of urinary 8-OHdG was examined in 116 Chinese children with acute leukemia (94 acute lymphoid leukemia, ALL, 22 acute myeloid leukemia, AML), and its correlation with urinary metal elements was investigated.
  • Our result showed that the level of urinary 8-OHdG in children with acute leukemia before treatment was significantly elevated compared with that in normal controls (11.92 +/- 15.42 vs. 4.03 +/- 4.70 ng/mg creatinine, P < 0.05).
  • In particular, urinary 8-OHdG was higher in children with acute leukemia aged under 3 years (20.86 +/- 21.75 ng/mg creatinine) than in those aged 3-15 years (8.09 +/- 9.65 ng/mg creatinine), whereas no differences were shown in terms of gender, parental smoking and education, household income, place of residence, and use of paracetamol.
  • In addition, urinary 8-OHdG levels were similar among different subtypes of acute lymphoid leukemia (ALL) patients.
  • Furthermore, linear regression analysis revealed a significant correlation between urinary 8-OHdG and urinary Cr, but not Fe or As, in group aged <3 years compared with group aged 3-15 years (P = 0.041), indicating that the metal elements may be involved in increasing urinary 8-OHdG level in younger children with acute leukemia.
  • Our results suggest that children with acute leukemia undergo an increased risk of oxidative DNA damage, which may be correlated with high level of Cr exposure in Chinese children with acute leukemia.
  • [MeSH-major] Carcinogens / metabolism. Deoxyguanosine / analogs & derivatives. Leukemia, Myeloid, Acute / urine. Precursor Cell Lymphoblastic Leukemia-Lymphoma / urine

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18979530.001).
  • [ISSN] 1522-7278
  • [Journal-full-title] Environmental toxicology
  • [ISO-abbreviation] Environ. Toxicol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carcinogens; 0 / Metals; 88847-89-6 / 8-oxo-7-hydrodeoxyguanosine; G9481N71RO / Deoxyguanosine
  •  go-up   go-down


8
Advertisement
4. Gelfand MS, Cleveland KO, Brewer SC: Rhodococcus equi pneumonia in a patient with fludarabine-treated chronic lymphocytic leukemia and CD4-lymphopenia. Am J Med Sci; 2010 Jul;340(1):80-1
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rhodococcus equi pneumonia in a patient with fludarabine-treated chronic lymphocytic leukemia and CD4-lymphopenia.
  • Cavitary pneumonia caused by Rhodococcus equi may occur in patients with defective cell-mediated immunity.
  • Prolonged CD4 lymphopenia may develop in patients with chronic lymphocytic leukemia who receive fludarabine.
  • The authors report the first case of a patient with chronic lymphocytic leukemia who developed R equi pneumonia after fludarabine therapy.
  • [MeSH-major] Actinomycetales Infections / microbiology. Leukemia, Lymphoid / drug therapy. Lymphopenia / drug therapy. Pneumonia, Bacterial / microbiology. Rhodococcus equi / isolation & purification
  • [MeSH-minor] Aged, 80 and over. Anti-Bacterial Agents / therapeutic use. Antineoplastic Agents / therapeutic use. Bronchoalveolar Lavage Fluid / microbiology. CD4 Lymphocyte Count. Chronic Disease. Female. Humans. Opportunistic Infections / microbiology. Vidarabine / analogs & derivatives. Vidarabine / therapeutic use


85. Saygili EI, Aksoy N, Pehlivan M, Sever T, Yilmaz M, Cimenci IG, Pehlivan S: Enzyme levels and G-463A polymorphism of myeloperoxidase in chronic lymphocytic leukemia and multiple myeloma. Leuk Lymphoma; 2009 Dec;50(12):2030-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Enzyme levels and G-463A polymorphism of myeloperoxidase in chronic lymphocytic leukemia and multiple myeloma.
  • The aim of this study was to investigate how myeloperoxidase (MPO) G-463A gene polymorphism and enzyme levels varied among patients with chronic lymphocytic leukemia (CLL) and multiple myeloma (MM) and to find the relationship between the MPO gene, enzyme levels, and clinical parameters.
  • In accordance with the results of the study, we assess that the increase in the MPO enzyme level in the patient groups with CLL and MM generated bactericidal effects as well as the increased formation of ROP, thus setting off a pro-cell death pathway and playing a role on the pathogenesis of lymphoproliferative malignancies through this mechanism.
  • [MeSH-major] Leukemia, Lymphocytic, Chronic, B-Cell / genetics. Multiple Myeloma / genetics. Peroxidase / genetics


86. Kalac M, Suvic-Krizanic V, Ostojic S, Kardum-Skelin I, Barsic B, Jaksica B: Central nervous system involvement of previously undiagnosed chronic lymphocytic leukemia in a patient with neuroborreliosis. Int J Hematol; 2007 May;85(4):323-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Central nervous system involvement of previously undiagnosed chronic lymphocytic leukemia in a patient with neuroborreliosis.
  • Leukemic involvement of the central nervous system (CNS) in previously undiagnosed chronic lymphocytic leukemia (CLL) is very rare.
  • We report the case of a 62-year-old man with neuroborreliosis in which cytologic, immunocytochemical, and flow cytometry analyses revealed the presence of clonal B-lymphocytes in the cerebrospinal fluid (CSF).
  • The application of intrathecal dexamethasone therapy led to the disappearance of B-cell CLL (B-CLL) cells in the CSF.
  • [MeSH-major] Central Nervous System / pathology. Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy. Leukemia, Lymphocytic, Chronic, B-Cell / pathology. Leukemic Infiltration / drug therapy. Leukemic Infiltration / pathology. Lyme Neuroborreliosis / drug therapy. Lyme Neuroborreliosis / pathology

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • Hazardous Substances Data Bank. CHLORAMBUCIL .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Chemother Pharmacol. 1990;25(5):311-9 [2306790.001]
  • [Cites] Postgrad Med J. 2005 Mar;81(953):194-5 [15749798.001]
  • [Cites] Expert Opin Pharmacother. 2001 Jun;2(6):929-43 [11585009.001]
  • [Cites] Eur J Intern Med. 2003 Feb;14(1):49-52 [12554011.001]
  • [Cites] J Neuroimmunol. 2000 Oct 2;110(1-2):244-51 [11024556.001]
  • [Cites] Leuk Lymphoma. 2002 Jan;43(1):199-201 [11908730.001]
  • [Cites] Infect Immun. 2005 Feb;73(2):1014-22 [15664945.001]
  • [Cites] Br J Haematol. 1999 Mar;104(4):689-94 [10192427.001]
  • [Cites] Blood. 2000 Jul 15;96(2):776-7 [10950515.001]
  • [Cites] Ann Neurol. 1998 Oct;44(4):592-600 [9778257.001]
  • [Cites] Cancer Chemother Pharmacol. 1988;21(1):1-8 [3342460.001]
  • [Cites] J Infect Dis. 1998 Feb;177(2):401-8 [9466528.001]
  • [Cites] Leukemia. 1996 May;10(5):877-95 [8656686.001]
  • [Cites] Leuk Lymphoma. 2005 Apr;46(4):619-21 [16019494.001]
  • [Cites] Leuk Lymphoma. 1998 Feb;28(5-6):603-5 [9613992.001]
  • [Cites] J Clin Pathol. 1996 Aug;49(8):672-5 [8881921.001]
  • [Cites] Ann Hematol. 2002 Jul;81(7):402-4 [12185514.001]
  • [Cites] J Neuroophthalmol. 2005 Jun;25(2):113-5 [15937434.001]
  • [Cites] Leuk Lymphoma. 2003 Jul;44(7):1235-7 [12916878.001]
  • (PMID = 17483076.001).
  • [ISSN] 0925-5710
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Anti-Infective Agents; 0 / Antineoplastic Agents, Alkylating; 0 / Antineoplastic Agents, Hormonal; 18D0SL7309 / Chlorambucil; 7S5I7G3JQL / Dexamethasone; EC 3.4.24.35 / Matrix Metalloproteinase 9
  •  go-up   go-down


87. Schöttker B, Feuchtinger T, Schumm M, Klinker E, Handgretinger R, Einsele H, Stuhler G: Five donors-one recipient: modeling a mosaic of granulocytes, natural killer and T cells from cord-blood and third-party donors. Nat Clin Pract Oncol; 2008 May;5(5):291-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INVESTIGATIONS: Laboratory tests, immunophenotyping, cytogenetic analyses, bone-marrow biopsy, minimal residual disease analysis using quantitative real-time polymerase chain reaction, differential chimerism analysis using flow cytometry, mixed chimerism analysis, CT scans, electro-encephalography, cerebral magnetic resonance tomography.
  • DIAGNOSIS: Bcr-abl-positive and Philadelphia-chromosome-positive acute lymphoblastic leukemia, and primary graft failure complicated by invasive fungal infection and cytomegalovirus encephalitis.
  • MANAGEMENT: Double cord-blood rescue transplantation, third-party CD34-positive stem-cell rescue transplantation, third-party cytomegalovirus-specific T lymphocyte transplantation.
  • [MeSH-major] Cell Transplantation. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • [MeSH-minor] Adult. Cord Blood Stem Cell Transplantation. Granulocytes / transplantation. Humans. Killer Cells, Natural / transplantation. Male. Mosaicism. T-Lymphocytes / transplantation

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18364724.001).
  • [ISSN] 1743-4262
  • [Journal-full-title] Nature clinical practice. Oncology
  • [ISO-abbreviation] Nat Clin Pract Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


88. Pichiorri F, Trapasso F, Palumbo T, Aqeilan RI, Drusco A, Blaser BW, Iliopoulos D, Caligiuri MA, Huebner K, Croce CM: Preclinical assessment of FHIT gene replacement therapy in human leukemia using a chimeric adenovirus, Ad5/F35. Clin Cancer Res; 2006 Jun 01;12(11 Pt 1):3494-501
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preclinical assessment of FHIT gene replacement therapy in human leukemia using a chimeric adenovirus, Ad5/F35.
  • Adenovirus 5 (Ad5) virus or adeno-associated viral vectors have been used to study the tumor suppressor function of FHIT in solid tumors, but these tools have not been effective in leukemias.
  • EXPERIMENTAL DESIGN: Infection efficiency of Ad5/F35-FHIT and Ad5/F35-GFP viruses was tested in leukemia cell lines that lacked FHIT expression, and biological effects of successful infection were assessed.
  • An acute myelogenous leukemia, a chronic myelogenous leukemia, and four acute lymphoblastic leukemia human cell lines were examined as well as two EBV-transformed B lymphoblastoid cell lines that expressed endogenous FHIT.
  • RESULTS: Two of four acute lymphoblastic leukemia cell lines, Jurkat and MV4;11, which were efficiently infected with Ad5/F35-FHIT, underwent growth suppression and massive induction of apoptosis without apparent activation of caspase-8 or caspase-2 and late activation of caspase-3.
  • The two remaining infected acute lymphoblastic leukemia cell lines, Molt-3 and RS4;11, were apparently unaffected.
  • Restoration of FHIT expression in the chronic myelogenous leukemia K562 cell line and the acute myelogenous leukemia KG1a cell line also induced apoptosis but at later time points than seen in the acute lymphoblastic leukemia Jurkat and MV4;11 cell lines. I.v. injection of Ad5/F35-FHIT-infected Jurkat cells resulted in abrogation of tumorigenicity in the NOD/SCID xenogeneic engraftment model.
  • CONCLUSION: FHIT restoration in some FHIT-deficient leukemia cells induces both antiproliferative and proapoptotic effects involving the intrinsic caspase apoptotic pathway.
  • [MeSH-major] Acid Anhydride Hydrolases / genetics. Adenoviruses, Human / genetics. Gene Expression Regulation, Neoplastic / genetics. Genetic Therapy / methods. Leukemia / genetics. Neoplasm Proteins / genetics
  • [MeSH-minor] Animals. Apoptosis / drug effects. Apoptosis / genetics. Cell Cycle. Cell Line, Tumor. Cell Proliferation / drug effects. Disease Models, Animal. Drug Screening Assays, Antitumor. Enzyme Inhibitors / pharmacology. Gene Transfer Techniques. Genetic Vectors / genetics. Green Fluorescent Proteins / genetics. Humans. Kinetics. Mice. Mice, Inbred NOD. Mice, SCID. Structure-Activity Relationship. Transplantation, Heterologous. Xenograft Model Antitumor Assays

  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Clin Cancer Res. 2016 Dec 15;22(24):6304 [27856602.001]
  • (PMID = 16740775.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA56036; United States / NCI NIH HHS / CA / CA77738; United States / NCI NIH HHS / CA / CA78890; United States / NCI NIH HHS / CA / CA89341
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Enzyme Inhibitors; 0 / Neoplasm Proteins; 0 / fragile histidine triad protein; 147336-22-9 / Green Fluorescent Proteins; EC 3.6.- / Acid Anhydride Hydrolases
  •  go-up   go-down


89. Pettit GR, Thornhill AJ, Moser BR, Hogan F: Antineoplastic agents. 552. Oxidation of combretastatin A-1: trapping the o-quinone intermediate considered the metabolic product of the corresponding phosphate prodrug. J Nat Prod; 2008 Sep;71(9):1561-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Both phenazines 7 and 11 significantly inhibited (ED50 approximately 0.2 microg/mL) growth of the murine P388 lymphocytic leukemia cell line and provided a new SAR insight in the combretastatin series of naturally occurring anticancer drugs.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Anticancer Drug Des. 2000 Jun;15(3):203-16 [11049088.001]
  • [Cites] Chem Res Toxicol. 2007 Dec;20(12):1885-94 [17941699.001]
  • [Cites] Bioorg Med Chem. 2003 Jul 17;11(14):3179-91 [12818681.001]
  • [Cites] Int J Cancer. 2004 Sep 10;111(4):604-10 [15239140.001]
  • [Cites] J Nat Prod. 1987 Jan-Feb;50(1):119-31 [3598594.001]
  • [Cites] Experientia. 1989 Feb 15;45(2):209-11 [2920809.001]
  • [Cites] J Pharm Biomed Anal. 1990;8(3):307-12 [2094431.001]
  • [Cites] Pharmacol Ther. 1993 Aug;59(2):163-228 [8278462.001]
  • [Cites] J Med Chem. 1995 May 12;38(10):1666-72 [7752190.001]
  • [Cites] Anticancer Drug Des. 1995 Jun;10(4):299-309 [7786396.001]
  • [Cites] Anticancer Drug Des. 1998 Apr;13(3):183-91 [9595032.001]
  • [Cites] J Clin Invest. 2005 Nov;115(11):2992-3006 [16224539.001]
  • [Cites] Clin Cancer Res. 2006 Jul 1;12(13):4090-4 [16818709.001]
  • [Cites] Bioorg Med Chem. 2007 Jan 15;15(2):605-15 [17070061.001]
  • [Cites] Expert Opin Investig Drugs. 2007 Apr;16(4):451-65 [17371194.001]
  • [Cites] Curr Opin Oncol. 2008 Jan;20(1):19-24 [18043252.001]
  • [Cites] Biosci Biotechnol Biochem. 2001 Dec;65(12):2613-21 [11826955.001]
  • (PMID = 18729517.001).
  • [ISSN] 1520-6025
  • [Journal-full-title] Journal of natural products
  • [ISO-abbreviation] J. Nat. Prod.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA090441-05; United States / NCI NIH HHS / CA / R01 CA090441; United States / NCI NIH HHS / CA / R01 CA090441-01; United States / NCI NIH HHS / CA / R56 CA090441-06A1; United States / NCI NIH HHS / CA / R01 CA090441-02; United States / NCI NIH HHS / CA / 2R56 CA090441-06A1; United States / NCI NIH HHS / CA / R01 CA090441-04; United States / NCI NIH HHS / CA / R01 CA090441-03; United States / NCI NIH HHS / CA / R01 CA90441-01-05; United States / NCI NIH HHS / CA / R56 CA090441
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Biological Products; 0 / Prodrugs; 0 / Quinones; 0 / Stilbenes; 109971-63-3 / combretastatin A-1; I5590ES2QZ / fosbretabulin
  • [Other-IDs] NLM/ NIHMS86312; NLM/ PMC2756244
  •  go-up   go-down


90. Uckun FM, Dibirdik I, Qazi S, Yiv S: Therapeutic nanoparticle constructs of a JAK3 tyrosine kinase inhibitor against human B-lineage ALL cells. Arzneimittelforschung; 2010;60(4):210-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Therapeutic nanoparticle constructs of a JAK3 tyrosine kinase inhibitor against human B-lineage ALL cells.
  • Notably, WHI-P131-NP was capable of causing apoptotic death in primary leukemia cells from chemotherapy-resistant acute lymphoblastic leukemia (ALL) as well as chronic lymphocytic leukemia (CLL) patients.
  • These experimental results demonstrate that the nanotechnology-enabled delivery of WHI-P131 shows therapeutic potential against leukemias with constitutive activation of the JAK3-STAT3/STAT5 molecular target.
  • [MeSH-major] Antineoplastic Agents. Janus Kinase 3 / antagonists & inhibitors. Leukemia, B-Cell / drug therapy. Leukemia, Biphenotypic, Acute / drug therapy. Protein Kinase Inhibitors / administration & dosage. Protein Kinase Inhibitors / pharmacology. Quinazolines / administration & dosage. Quinazolines / pharmacology
  • [MeSH-minor] Animals. Apoptosis / drug effects. Calibration. Cell Lineage. Chemistry, Pharmaceutical. Chromatography, High Pressure Liquid. Female. Humans. Liposomes. Mice. Mice, SCID. Nanoparticles. Osmolar Concentration. Particle Size

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Arzneimittelforschung. 2010;60(5):286
  • (PMID = 20486472.001).
  • [ISSN] 0004-4172
  • [Journal-full-title] Arzneimittel-Forschung
  • [ISO-abbreviation] Arzneimittelforschung
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Liposomes; 0 / Protein Kinase Inhibitors; 0 / Quinazolines; 0 / WHI P131; EC 2.7.10.2 / Janus Kinase 3
  •  go-up   go-down


91. Tedeschi A, Montillo M, Strocchi E, Cafro AM, Tresoldi E, Intropido L, Nichelatti M, Marbello L, Baratè C, Camaggi CM, Morra E: High-dose idarubicin in combination with Ara-C in patients with relapsed or refractory acute lymphoblastic leukemia: a pharmacokinetic and clinical study. Cancer Chemother Pharmacol; 2007 May;59(6):771-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-dose idarubicin in combination with Ara-C in patients with relapsed or refractory acute lymphoblastic leukemia: a pharmacokinetic and clinical study.
  • OBJECTIVE: High dose (HD) Ara-C combined with a single HD idarubicin dose (IDA) is an efficient and safe salvage regimen for patients with refractory or relapsed acute lymphoblastic leukemia as indicated by phase II studies.
  • PATIENTS AND METHODS: Twenty-five patients with refractory or relapsed acute lymphoblastic leukemia received Ara-C 3 g/m2 from days 1-5, idarubicin (HD-IDA) 40 mg/m2 as rapid intravenous (i.v.) infusion on day 3 and subcutaneous G-CSF 5 microg/kg from day 7 until PMN recovery.
  • RESULTS: Eleven patients (44%, 95% CI: 23-65%) achieved complete remission with median disease free survival for 6 months.
  • Our data do not allow us to clearly attribute this behavior to a pharmacokinetic non-linearity since the baseline creatinine clearance, even within normal values, and patient age are significantly different in the two groups.
  • [MeSH-minor] Adolescent. Adult. Disease-Free Survival. Female. Humans. Male. Middle Aged. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism. Recurrence. Remission Induction. Survival Analysis

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Hazardous Substances Data Bank. CYTARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17256136.001).
  • [ISSN] 0344-5704
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; ZRP63D75JW / Idarubicin
  •  go-up   go-down


92. Sazawal S, Bakhshi S, Raina V, Swaroop C, Saxena R: Detection and clinical relevance of BCR-ABL fusion gene in childhood T-lineage acute lymphoblastic leukemia: a report on 4 cases. J Pediatr Hematol Oncol; 2009 Nov;31(11):850-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection and clinical relevance of BCR-ABL fusion gene in childhood T-lineage acute lymphoblastic leukemia: a report on 4 cases.
  • The bcr-abl rearrangement has rarely been reported in T-lineage acute lymphoblastic leukemia and the clinical significance of this translocation is currently unknown.
  • We screened 28 children with T-lineage acute lymphoblastic leukemia at diagnosis by reverse transcription polymerase chain reaction for major and minor break point regions of bcr-abl fusion gene.
  • [MeSH-major] Chromosomes, Human, Pair 22 / genetics. Chromosomes, Human, Pair 9 / genetics. Genes, abl / genetics. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / genetics. Translocation, Genetic


93. Murati A, Gervais C, Carbuccia N, Finetti P, Cervera N, Adélaïde J, Struski S, Lippert E, Mugneret F, Tigaud I, Penther D, Bastard C, Poppe B, Speleman F, Baranger L, Luquet I, Cornillet-Lefebvre P, Nadal N, Nguyen-Khac F, Pérot C, Olschwang S, Bertucci F, Chaffanet M, Lessard M, Mozziconacci MJ, Birnbaum D, Groupe Francophone de Cytogénétique Hématologique: Genome profiling of acute myelomonocytic leukemia: alteration of the MYB locus in MYST3-linked cases. Leukemia; 2009 Jan;23(1):85-94
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genome profiling of acute myelomonocytic leukemia: alteration of the MYB locus in MYST3-linked cases.
  • The t(8;16)(p11;p13) is a rare translocation involved in de novo and therapy-related myelomonocytic and monocytic acute leukemia.
  • MYST3-linked acute myeloid leukemias (AMLs) share specific clinical and biological features and a poor prognosis.
  • We have established the genome and gene expression profiles of a multicentric series of 61 M4/M5 AMLs including 18 MYST3-linked AMLs by using array comparative genome hybridization (aCGH) (n=52) and DNA microarrays (n=44), respectively.
  • These features, reminiscent of T-cell acute lymphoid leukemia (ALL), suggest the targeting of a common T-myeloid progenitor.
  • [MeSH-major] Gene Expression Profiling / methods. Genes, myb / genetics. Histone Acetyltransferases / genetics. Leukemia, Myelomonocytic, Acute / genetics

  • Genetic Alliance. consumer health - Acute Myelomonocytic Leukemia.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18818702.001).
  • [ISSN] 1476-5551
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD4; 0 / Homeodomain Proteins; 0 / Proto-Oncogene Proteins c-myb; 157907-48-7 / HoxA protein; EC 2.3.1.48 / Histone Acetyltransferases; EC 2.3.1.48 / KAT6A protein, human
  •  go-up   go-down


94. Beyan C, Kaptan K, Ifran A: Coexistence of chronic lymphocytic leukemia and Hashimoto's thyroiditis. Ann Hematol; 2006 Nov;85(11):811-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Coexistence of chronic lymphocytic leukemia and Hashimoto's thyroiditis.
  • [MeSH-major] Hashimoto Disease / etiology. Leukemia, Lymphocytic, Chronic, B-Cell / complications

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16845514.001).
  • [ISSN] 0939-5555
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Germany
  •  go-up   go-down


95. Dasanu CA: Intrinsic and treatment-related immune alterations in chronic lymphocytic leukaemia and their impact for clinical practice. Expert Opin Pharmacother; 2008 Jun;9(9):1481-94
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intrinsic and treatment-related immune alterations in chronic lymphocytic leukaemia and their impact for clinical practice.
  • BACKGROUND: Chronic lymphocytic leukaemia patients harbour important impairments in both their cellular- and humoral-mediated immunity, which accounts for their notorious susceptibility to a multitude of infections and various autoimmune cytopenias.
  • It has also been shown that the rate of second cancers is increased in chronic lymphocytic leukaemia.
  • OBJECTIVE: The aim of this study was to review the immune alterations in untreated and treated chronic lymphocytic leukaemia and define their impact for clinical practice.
  • METHODS: The author gives a comprehensive review of the most relevant preclinical and clinical studies pertaining to various immune abnormalities and infectious complications in both untreated and treated chronic lymphocytic leukaemia.
  • Landmark clinical trials involving the contemporary chronic lymphocytic leukaemia chemo- and immunotherapies, alone or in combination, as well as the main epidemiological studies establishing the increased rate of second cancers in chronic lymphocytic leukaemia are also discussed.
  • RESULTS/CONCLUSIONS: Iatrogenic immunosuppression in chronic lymphocytic leukaemia alters the pattern of opportunistic infections, can cause autoimmune cytopenias and might further increase the rate of second malignancies in patients whose disease already places them at a greater risk.
  • Careful consideration of existing risk factors in chronic lymphocytic leukaemia could establish the optimal screening and follow-up schedule for chronic lymphocytic leukaemia patients as its therapeutics evolves.
  • [MeSH-major] Antineoplastic Agents. Immune System Diseases / chemically induced. Immune Tolerance / drug effects. Leukemia, Lymphocytic, Chronic, B-Cell. Neoplasms, Second Primary. Opportunistic Infections

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Immune System and Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18518779.001).
  • [ISSN] 1744-7666
  • [Journal-full-title] Expert opinion on pharmacotherapy
  • [ISO-abbreviation] Expert Opin Pharmacother
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 69
  •  go-up   go-down


96. Qu L, Li Q, Jiang H, Gu L, Zhang Q, Wang C, Li J: Effect of anti-mouse CD52 monoclonal antibody on mouse intestinal intraepithelial lymphocytes. Transplantation; 2009 Sep 27;88(6):766-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: CD52 monoclonal antibody (mAb) has been used therapeutically in lymphocytic leukemia, autoimmune disease, and organ transplantation.
  • [MeSH-minor] Animals. Antigens, CD. Antigens, Neoplasm. Apoptosis / immunology. Cell Survival / immunology. Epithelium / immunology. Epithelium / metabolism. Epithelium / pathology. Immunity, Mucosal. Injections, Subcutaneous. Lymphocyte Count. Lymphocyte Depletion / adverse effects. Male. Mice. Mice, Inbred C57BL. Permeability. Transplantation Immunology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19920775.001).
  • [ISSN] 1534-6080
  • [Journal-full-title] Transplantation
  • [ISO-abbreviation] Transplantation
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, CD; 0 / Antigens, Neoplasm; 0 / CD52 antigen; 0 / Glycoproteins
  •  go-up   go-down


97. Milne E, Laurvick CL, de Klerk N, Robertson L, Thompson JR, Bower C: Trends in childhood acute lymphoblastic leukemia in Western Australia, 1960-2006. Int J Cancer; 2008 Mar 1;122(5):1130-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Trends in childhood acute lymphoblastic leukemia in Western Australia, 1960-2006.
  • Increases in the incidence of childhood acute lymphoblastic leukemia (ALL) have been reported in some countries, while other reports from similar geographical regions have indicated stable rates.
  • The reasons for the discrepancies have been debated in the literature, with the focus on whether the observed increases are "real" or an artifact resulting from improvements in diagnosis, case ascertainment and population coverage over time.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / epidemiology


98. Nabhan C: Frontline therapy for chronic lymphocytic leukemia: the dilemma continues. Clin Cancer Res; 2008 Jul 1;14(13):4353
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Frontline therapy for chronic lymphocytic leukemia: the dilemma continues.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. VIDARABINE .
  • Hazardous Substances Data Bank. NOVANTRONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Clin Cancer Res. 2008 Jan 1;14(1):155-61 [18172266.001]
  • (PMID = 18594019.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Comment; Letter
  • [Publication-country] United States
  • [Chemical-registry-number] 8N3DW7272P / Cyclophosphamide; BZ114NVM5P / Mitoxantrone; FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine
  •  go-up   go-down


99. Al'-Radi LS, Samoĭlova RS, Tikhonova LIu, Diagileva OA, Obukhova TN, Kaplanskaia IB, Gretsov EM, Vorob'ev IA, Kremenetskaia AM, Kravchenko SK: [Combination of chronic lymphoid leukemia and hairy cell leukemia]. Ter Arkh; 2006;78(7):84-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Combination of chronic lymphoid leukemia and hairy cell leukemia].
  • [MeSH-major] Leukemia, Hairy Cell / complications. Leukemia, Lymphocytic, Chronic, B-Cell / complications

  • Genetic Alliance. consumer health - Hairy Cell Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16944757.001).
  • [ISSN] 0040-3660
  • [Journal-full-title] Terapevticheskiĭ arkhiv
  • [ISO-abbreviation] Ter. Arkh.
  • [Language] rus
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


100. Sweetenham JW: Lymphoblastic lymphoma in adults. Curr Hematol Malig Rep; 2006 Dec;1(4):241-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymphoblastic lymphoma in adults.
  • Understanding of the pathogenesis and biology of precursor T-cell and B-cell neoplasms has advanced significantly with the description of gene expression profiling studies, especially in T-cell disease.
  • Optimal treatment strategies for adult lymphoblastic lymphoma are uncertain, although current evidence supports the use of regimens similar to those used in acute lymphoblastic leukemia, with intensive induction therapy, central nervous system prophylaxis, and prolonged consolidation maintenance therapy.
  • Current studies do not demonstrate a benefit from stem cell transplantation in first remission, although this approach is probably beneficial in relapsed disease.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. B-Lymphocytes / pathology. Child. Combined Modality Therapy. Gene Expression Regulation, Neoplastic. Gene Rearrangement. Hematopoietic Stem Cell Transplantation. Humans. Mediastinal Neoplasms / drug therapy. Mediastinal Neoplasms / pathology. Mediastinal Neoplasms / radiotherapy. Multicenter Studies as Topic / statistics & numerical data. Prognosis. Randomized Controlled Trials as Topic / statistics & numerical data. Remission Induction. Salvage Therapy. T-Lymphocytes / pathology. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Lymphoblastic lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1993 Sep 30;329(14 ):987-94 [8141877.001]
  • [Cites] Leuk Lymphoma. 1994 Oct;15(3-4):291-6 [7866277.001]
  • [Cites] J Clin Oncol. 2001 Jun 1;19(11):2927-36 [11387366.001]
  • [Cites] J Nucl Med. 2002 Aug;43(8):1018-27 [12163626.001]
  • [Cites] Am J Clin Pathol. 2004 Feb;121(2):268-74 [14983942.001]
  • [Cites] Ann Intern Med. 1978 Sep;89(3):319-24 [686542.001]
  • [Cites] Leuk Lymphoma. 1999 Dec;36(1-2):101-8 [10613454.001]
  • [Cites] Cancer Cell. 2002 Feb;1(1):75-87 [12086890.001]
  • [Cites] Br J Haematol. 1989 Sep;73(1):82-7 [2803982.001]
  • [Cites] Blood. 2002 Jun 15;99(12):4379-85 [12036865.001]
  • [Cites] Blood. 1999 Jun 1;93(11):3931-9 [10339502.001]
  • [Cites] Cancer. 1987 Jul 15;60(2):183-90 [2954631.001]
  • [Cites] Blood. 2003 Jul 1;102(1):262-8 [12637319.001]
  • [Cites] Cancer. 1981 Dec 1;48(11):2347-57 [6895347.001]
  • [Cites] Ann Oncol. 1995 May;6(5):445-51 [7545428.001]
  • [Cites] J Clin Oncol. 1994 Jul;12(7):1358-65 [8021726.001]
  • [Cites] J Clin Oncol. 1986 Jan;4(1):57-67 [3510283.001]
  • [Cites] Blood. 2004 Jan 15;103(2):442-50 [14504110.001]
  • [Cites] J Clin Invest. 1985 Jul;76(1):248-53 [2410458.001]
  • [Cites] J Clin Oncol. 1986 Nov;4(11):1628-37 [3772416.001]
  • [Cites] Ann Oncol. 1990;1(2):141-6 [2078494.001]
  • [Cites] Mol Diagn. 1996 Jun;1(2):139-151 [10330209.001]
  • [Cites] Leukemia. 2005 Jun;19(6):945-52 [15800666.001]
  • [Cites] J Pathol. 1999 Jul;188(3):267-70 [10419594.001]
  • [Cites] Blood. 2003 Apr 1;101(7):2476-82 [12456505.001]
  • [Cites] J Clin Oncol. 1992 Apr;10(4):644-6 [1548528.001]
  • [Cites] Blood. 1997 Jun 1;89(11):3909-18 [9166827.001]
  • [Cites] Blood. 2004 Sep 15;104(6):1624-30 [15178574.001]
  • [Cites] Bone Marrow Transplant. 2003 Apr;31(8):667-78 [12692607.001]
  • [Cites] Blood. 2005 Aug 15;106(4):1376-81 [15860666.001]
  • [Cites] Cancer. 2003 Sep 15;98(6):1283-91 [12973853.001]
  • [Cites] Ann Oncol. 1998 Jun;9(6):619-25 [9681075.001]
  • [Cites] Leukemia. 2003 Nov;17(11):2220-4 [14576732.001]
  • [Cites] N Engl J Med. 1983 Mar 10;308(10):559-65 [6338381.001]
  • [Cites] Bone Marrow Transplant. 1992 Jul;10(1):33-8 [1515876.001]
  • [Cites] Cancer. 2002 May 15;94(10):2738-44 [12173345.001]
  • [Cites] Mod Pathol. 2004 Apr;17(4):423-9 [14976526.001]
  • [Cites] Leuk Lymphoma. 1996 Nov;23(5-6):577-82 [9031089.001]
  • [Cites] Cancer. 1979 Dec;44(6):1990-9 [389403.001]
  • [Cites] Blood. 1981 Apr;57(4):679-84 [6970598.001]
  • (PMID = 20425319.001).
  • [ISSN] 1558-822X
  • [Journal-full-title] Current hematologic malignancy reports
  • [ISO-abbreviation] Curr Hematol Malig Rep
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 42
  •  go-up   go-down






Advertisement